Literature DB >> 26243972

PILL Series. The 'problematic' asthma patient.

Swee Leng Kui1, Choon How How2, Jansen Koh3.   

Abstract

Asthma is a reversible chronic inflammatory disorder of the airways that can be effectively controlled without causing any lifestyle limitation or burden on the quality of life of the majority of asthma patients. However, persistently uncontrolled asthma can be frustrating for both the patient and the managing physician. Patients who fail to respond to high-intensity asthma treatment fall into the category of 'problematic' asthma, which is further subdivided into 'difficult' asthma and 'severe refractory' asthma. Establishing the correct diagnosis of asthma and addressing comorbidities, compliance, inhaler technique and environmental triggers are essential when dealing with 'problematic' asthma patients. A systemic approach is also crucial in managing such patients. This is pertinent for general practitioners, as the majority of asthma patients are diagnosed and managed at the primary care level.

Entities:  

Keywords:  asthma; difficult; primary care; problematic; severe refractory

Mesh:

Year:  2015        PMID: 26243972      PMCID: PMC4520914          DOI: 10.11622/smedj.2015106

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  13 in total

1.  Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.

Authors:  J C Virchow; A Prasse; I Naya; L Summerton; A Harris
Journal:  Am J Respir Crit Care Med       Date:  2000-08       Impact factor: 21.405

2.  A study of a multi-level intervention to improve non-adherence in difficult to control asthma.

Authors:  Jacqueline Gamble; Michael Stevenson; Liam G Heaney
Journal:  Respir Med       Date:  2011-04-20       Impact factor: 3.415

Review 3.  Severe refractory asthma: an update.

Authors:  Reinier R L Wener; Elisabeth H Bel
Journal:  Eur Respir Rev       Date:  2013-09-01

4.  Tiotropium in asthma poorly controlled with standard combination therapy.

Authors:  Huib A M Kerstjens; Michael Engel; Ronald Dahl; Pierluigi Paggiaro; Ekkehard Beck; Mark Vandewalker; Ralf Sigmund; Wolfgang Seibold; Petra Moroni-Zentgraf; Eric D Bateman
Journal:  N Engl J Med       Date:  2012-09-02       Impact factor: 91.245

5.  A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma.

Authors:  D J Evans; D A Taylor; O Zetterstrom; K F Chung; B J O'Connor; P J Barnes
Journal:  N Engl J Med       Date:  1997-11-13       Impact factor: 91.245

Review 6.  The costs of asthma.

Authors:  P J Barnes; B Jonsson; J B Klim
Journal:  Eur Respir J       Date:  1996-04       Impact factor: 16.671

Review 7.  Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).

Authors:  Elisabeth H Bel; Ana Sousa; Louise Fleming; Andrew Bush; K Fan Chung; Jennifer Versnel; Ariane H Wagener; Scott S Wagers; Peter J Sterk; Chris H Compton
Journal:  Thorax       Date:  2010-11-23       Impact factor: 9.139

8.  Systematic assessment of difficult-to-treat asthma.

Authors:  D S Robinson; D A Campbell; S R Durham; J Pfeffer; P J Barnes; K F Chung
Journal:  Eur Respir J       Date:  2003-09       Impact factor: 16.671

9.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.

Authors:  Kian Fan Chung; Sally E Wenzel; Jan L Brozek; Andrew Bush; Mario Castro; Peter J Sterk; Ian M Adcock; Eric D Bateman; Elisabeth H Bel; Eugene R Bleecker; Louis-Philippe Boulet; Christopher Brightling; Pascal Chanez; Sven-Erik Dahlen; Ratko Djukanovic; Urs Frey; Mina Gaga; Peter Gibson; Qutayba Hamid; Nizar N Jajour; Thais Mauad; Ronald L Sorkness; W Gerald Teague
Journal:  Eur Respir J       Date:  2013-12-12       Impact factor: 16.671

10.  Recommendation for optimal management of severe refractory asthma.

Authors:  Jaymin B Morjaria; Riccardo Polosa
Journal:  J Asthma Allergy       Date:  2010-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.